0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover8150.50%IV202.53%PremiumMay 17, 2024Expiry Date1.34Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.9291Delta0.3368Gamma--Leverage Ratio-1.0764Theta0.0000Rho0.00Eff Leverage0.0000Vega
Atara Biotherapeutics Stock Discussion
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
SEC announcement· 4 mins ago
Moomoo 24/7· 1 min ago
SEC announcement· 16:29
MT Newswires· 4 mins ago
Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for systemic lupus erythematosus, or lupus nephritis that affects the kidneys.
ATA3219 is an allogeneic chimeric antigen receptor T-cell therapy that ...
SEC announcement· 7 mins ago
No comment yet